Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imugene Limited ( (AU:IMU) ) just unveiled an update.
Imugene Limited has announced an Extraordinary General Meeting (EGM) scheduled for June 26, 2025, to be held both in-person in Sydney and online via Zoom. This meeting will allow shareholders to participate in company decisions, reflecting Imugene’s commitment to engaging stakeholders and ensuring their involvement in the company’s strategic direction.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a biotechnology company focused on developing immunotherapies for cancer treatment. The company specializes in harnessing the body’s immune system to target and eradicate cancer cells, positioning itself within the innovative cancer treatment industry.
Average Trading Volume: 23,879,383
Technical Sentiment Signal: Sell
Current Market Cap: A$126.9M
See more data about IMU stock on TipRanks’ Stock Analysis page.